Graves disease: latest understanding of pathogenesis and treatment options

• Published in: Nature reviews. Endocrinology Vol. 20; no. 11; p. 647
• Main Authors: Lanzolla, Giulia, Marinò, Michele, Menconi, Francesca
• Format: Journal Article
• Language: English
• Published: England 01.11.2024
• Subjects: Antithyroid Agents - therapeutic use; Autoantibodies - immunology; Glucocorticoids - therapeutic use; Graves Disease - immunology; Graves Disease - therapy; Graves Ophthalmopathy - drug therapy; Graves Ophthalmopathy - immunology; Graves Ophthalmopathy - therapy; Humans; Receptor, IGF Type 1 - antagonists & inhibitors; Receptor, IGF Type 1 - immunology; Receptor, IGF Type 1 - metabolism; Receptors, Thyrotropin - immunology
• ISSN: 1759-5037
• DOI: 10.1038/s41574-024-01016-5

Graves disease is the most common cause of hyperthyroidism in iodine-sufficient areas. The main responsible mechanism is related to autoantibodies that bind and activate the thyrotropin receptor (TSHR). Although Graves hyperthyroidism is relatively common, no causal treatment options are available. Established treatment modalities are antithyroid drugs, which reduce thyroid hormone synthesis, radioactive iodine and surgery. However, emerging drugs that target the main autoantigen (monoclonal antibodies, small molecules, peptides) or block the immune pathway have been recently tested in clinical trials. Graves disease can involve the thyroid exclusively or it can be associated with extrathyroidal manifestations, among which Graves orbitopathy is the most common. The presence of Graves orbitopathy can change the management of the disease. An established treatment for moderate-to-severe Graves orbitopathy is intravenous glucocorticoids. However, recent advances in understanding the pathogenesis of Graves orbitopathy have allowed the development of new target-based therapies by blocking pro-inflammatory cytokine receptors, lymphocytic infiltration or the insulin-like growth factor 1 receptor (IGF1R), with several clinical trials providing promising results. This article reviews the new discoveries in the pathogenesis of Graves hyperthyroidism and Graves orbitopathy that offer several important tools in disease management.